Successful leukocytapheresis therapy in a patient with rheumatoid arthritis on maintenance hemodialysis
- 80 Downloads
We report the case of a 44-year-old female undergoing maintenance hemodialysis in whom early-phase rheumatoid arthritis (RA) was successfully treated by leukocytapheresis (LCAP). The effects of prednisone, tacrolimus, and etanercept were limited, but LCAP was highly effective and its efficacy continued even after cessation of LCAP. Moreover, remission was maintained for 2 years after discontinuation of medication. LCAP may be an important treatment option for RA patients with end-stage renal failure who are on hemodialysis.
KeywordsLeukocytapheresis (LCAP) Rheumatoid arthritis Hemodialysis Drug-free remission
- 14.Hidaka T, Suzuki K, Matsuki Y, Takamizawa-Matsumoto M, Okada M, Ishizuka T, et al. Changes in CD4+ T lymphocyte subsets in circulating blood and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis. Ther Apher. 1999;3:178–85.PubMedCrossRefGoogle Scholar
- 18.Umekita K, Hidaka T, Ueno S, Takajo I, Kai Y, Nagatomo Y, et al. Leukocytapheresis (LCAP) decreases the level of platelet-derived microparticles (MPs) and increases the level of granulocytes-derived MPs: a possible connection with the effect of LCAP on rheumatoid arthritis. Mod Rheumatol. 2009;19:265–72.PubMedCrossRefGoogle Scholar
- 20.Hayashi W, Nishikawa Y, Tominaga T, Takashima H, Terada H, Ueki Y, et al. A case of eosinophilia caused by nafamostat mesilate following leukocytapheresis in a rheumatoid arthritis patient undergoing hemodialysis. Kyushu J Rheumatol. 2006;26:36–40.Google Scholar
- 24.van der Woude D, Young A, Jayakumar K, Mertens BJ, Toes RE, van der Heijde D, et al. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum. 2009;60:2262–71.PubMedCrossRefGoogle Scholar